Antiarrhythmic effects of cibenzoline

Area of Science:

• Cardiology
• Clinical Electrophysiology

Background:

• Ventricular tachyarrhythmias pose a significant clinical challenge.
• Antiarrhythmic therapy selection requires effective and safe agents.

Purpose of the Study:

• To compare the efficacy and electrophysiologic effects of cibenzoline succinate and procainamide for ventricular tachycardia.
• To evaluate the safety and effectiveness of chronic oral cibenzoline therapy.

Main Methods:

• Programmed electrical stimulation (PES) was used to assess antiarrhythmic drug efficacy.
• Intravenous cibenzoline and procainamide were administered and compared.
• Chronic oral cibenzoline therapy was evaluated in a subset of patients.

Main Results:

• Cibenzoline prevented ventricular tachycardia induction in 16/33 patients; procainamide in 21/31.
• Both drugs prolonged PR, QRS, and QTc intervals with minor blood pressure changes.
• Chronic oral cibenzoline reduced ventricular ectopy and tachycardia events but led to discontinuation in 5/13 patients due to breakthrough arrhythmias.

Conclusions:

• Cibenzoline succinate demonstrated antiarrhythmic properties comparable to procainamide in electrophysiologic testing.
• Chronic oral cibenzoline therapy can effectively reduce ventricular ectopy and tachycardia events.
• Careful patient selection is warranted due to potential for breakthrough arrhythmias with cibenzoline.